Is Evolent Health, Inc. (EVH) Overvalued?
We dive into why Evolent Health, Inc. (EVH) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Cynthia McLaughlin
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | EVH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $531.4 | $200.5 | 37% |
|
| Shares Out (Mil) | 112.5 | 47.8 | 64% |
|
| Institutional Ownership | 97.6% | 79.0% | 75% |
|
| Float (Mil) | 94.1 | 39.8 | 60% |
|
| Beta | na | 1.17 | na |
|
| Avg Daily Volume (000s) | 3,523 | 331 | 89% |
|
| Price Change (52-week) |
(47.8%) | 44.9% | 15% |
|
| Growth | EVH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 11.8% | 73% |
|
| Net Income (5yr) | (9.8%) | 2.7% | 29% |
|
| EPS (5yr) | (5.2%) | 15.5% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (62.6%) | (15.8%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | $0.060 | $0.200 | $0.391 | |
| Month Ago EPS | $0.054 | $0.197 | $0.385 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.053 | $0.196 | $0.404 | |
| Year/Year Chg | (123.8%) | (103.9%) | (110.5%) | |
| Financials | EVH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,097 | $202 | 61% |
|
| Net Income (TTM) (Mil) | ($505) | ($9) | 3% |
|
| EPS (TTM) | ($4.542) | ($0.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | $54 | ($1) | 47% |
|
| Net Cash Flow (TTM) (Mil) | ($37) | $3 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $969 | $18 | 66% |
|
| Enterprise Value (Q1) (Mil) | na | $197 | na |
|
| Valuation | EVH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.38 | 1.38 | 35% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.4 | na |
|
| Ratios | EVH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 17.2% | 61.6% | 17% |
|
| Net Margin | (24.1%) | (24.1%) | 16% |
|
| ROA | (22.8%) | (21.8%) | 19% |
|
| ROE | (79.0%) | (6.7%) | 11% |
|
| Liabilities to Assets | 80.6% | 32.1% | 75% |
|
| F-Score | 6 | 4 | 67% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | -2.4% |
| +/- S&P 500: | -9.9 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors